Medical Weight Management
A mobile, provider-guided weight-management program exploring tirzepatide, semaglutide, and the investigational option retatrutide. Every plan begins with a consultation — eligibility, treatment approach, and any medication are determined by your treating provider.
Medication-supported weight wellness, guided by your provider
Brillaré's Medical Weight Management program is a consultation-led approach to healthy weight. Rather than a one-size-fits-all menu, your journey begins with an honest conversation about your goals, lifestyle, and health history. From there, your treating provider determines whether a medication-supported plan is appropriate for you.
We explore tirzepatide and semaglutide — medications that work through GLP-1 receptor pathways to help regulate appetite and fullness — and we provide accurate educational information about retatrutide, an investigational option that is not currently FDA-approved. No specific medication, dosing schedule, or expected weight-loss amount is promised in advance.
How the program works
01Request a consultation. Submit your request and our coordinator reaches out to confirm coverage and scheduling across Central Florida.
02Provider evaluation. Your treating provider reviews your goals and history and determines whether a medication-supported plan is appropriate.
03Personalized plan & monitoring. If you move forward, your plan and any follow-up are guided by your provider based on your individual response.
Three paths, one consultation-led approach
A medication that targets both GIP and GLP-1 receptors. It may help reduce appetite, increase feelings of fullness, and support weight management alongside healthy lifestyle changes.
Tirzepatide
A GLP-1 medication that helps regulate appetite and promote longer-lasting fullness, supporting reduced food intake and long-term weight-management goals.
Semaglutide
An investigational medication that targets GLP-1, GIP, and glucagon receptors and is being studied for weight management and metabolic health. Retatrutide is not currently FDA-approved and should not be presented as an available clinical treatment outside an authorized clinical trial.
Understanding how these options differ
Tirzepatide and semaglutide are both medications that interact with the GLP-1 receptor pathway, which plays a role in appetite regulation and feelings of fullness. Tirzepatide additionally targets the GIP receptor. Retatrutide targets GLP-1, GIP, and glucagon receptors but remains investigational and is not currently FDA-approved.
Because each person's health profile is different, the right option — if any — is never chosen from a list. Your provider considers your goals, history, and preferences and recommends an approach suited to you. We do not publish dosing schedules, eligibility thresholds, or expected weight-loss amounts; those details belong to your personalized consultation and care.
Tirzepatide
Targets both GIP and GLP-1 receptors to help reduce appetite and support fullness alongside healthy lifestyle changes.
Semaglutide
A GLP-1 medication that helps regulate appetite and promote longer-lasting fullness for reduced food intake.
Retatrutide
Investigational · Targets GLP-1, GIP, and glucagon receptors. Not currently FDA-approved. Educational only.
Frequently Asked Questions
Start with a conversation
Request a Medical Weight Management consultation and let your provider guide the next step toward healthy weight, delivered with mobile convenience across Central Florida.